Drug intelligence / Profile preview

BW-0011

Development stage: Preclinical
Lead developer: Shanghai Argo Biopharmaceutical
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous, Intrathecal, Parenteral

Overview

BW-0011 is a small interfering RNA (siRNA) therapeutic candidate being developed by Argo Biopharma (also known as Chengdu Xinzhenghe Pharmaceutical Technology) for the treatment of Parkinson's disease. The drug utilizes RNA interference (RNAi) to specifically target and silence the expression of the SNCA gene, which encodes the alpha-synuclein protein. The accumulation and aggregation of alpha-synuclein are central to the pathogenesis of Parkinson's disease and other synucleinopathies. By reducing the production of alpha-synuclein at the source, BW-0011 aims to slow or halt disease progression. The program is currently in the preclinical stage of development and is part of Argo Biopharma's pipeline of RNA-based therapies.

Other names: SNCA siRNASNCA

Targets

Alpha-synuclein messenger RNA

Beyond the preview

Go deeper on BW-0011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BW-0011.

Explore the full profile